Literature DB >> 23800129

GLA mutation as a risk factor for later life small vessel ischaemic disease.

J F Meschia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23800129      PMCID： PMC3884043          DOI： 10.1111/ene.12216

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  11 in total

Review 1.  Blood pressure, proteinuria and nephropathy in Fabry disease.

Authors:  Gaurav Jain; David G Warnock
Journal:  Nephron Clin Pract       Date:  2010-11-11

2.  Enzyme replacement therapy and Fabry nephropathy.

Authors:  David G Warnock; Erica Daina; Giuseppe Remuzzi; Michael West
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-10       Impact factor: 8.237

Review 3.  Enzyme replacement therapy for Anderson-Fabry disease.

Authors:  Regina P El Dib; Paulo Nascimento; Gregory M Pastores
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 4.  Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.

Authors:  Yoshiyuki Suzuki
Journal:  Brain Dev       Date:  2013-01-03       Impact factor: 1.961

Review 5.  Hereditary cerebral small vessel diseases: a review.

Authors:  Antonio Federico; Ilaria Di Donato; Silvia Bianchi; Chiara Di Palma; Ilaria Taglia; Maria Teresa Dotti
Journal:  J Neurol Sci       Date:  2012-08-04       Impact factor: 3.181

6.  p.E66Q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly Japanese males.

Authors:  K Nakamura; Y Sekijima; K Nakamura; K Hattori; K Nagamatsu; Y Shimizu; M Yazaki; A Sakurai; F Endo; Y Fukushima; S-I Ikeda
Journal:  Eur J Neurol       Date:  2013-05-31       Impact factor: 6.089

Review 7.  Gene therapy for fabry disease: a review of the literature.

Authors:  Aritz Perez Ruiz de Garibay; María Angeles Solinís; Alicia Rodríguez-Gascón
Journal:  BioDrugs       Date:  2013-06       Impact factor: 5.807

8.  Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.

Authors:  Saskia M Rombach; Bouwien E Smid; Machtelt G Bouwman; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

9.  Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.

Authors:  Dominique P Germain; Roberto Giugliani; Derralynn A Hughes; Atul Mehta; Kathy Nicholls; Laura Barisoni; Charles J Jennette; Alexander Bragat; Jeff Castelli; Sheela Sitaraman; David J Lockhart; Pol F Boudes
Journal:  Orphanet J Rare Dis       Date:  2012-11-24       Impact factor: 4.123

10.  Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene.

Authors:  Malte Lenders; Thomas Duning; Michael Schelleckes; Boris Schmitz; Sonja Stander; Arndt Rolfs; Stefan-Martin Brand; Eva Brand
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.